Krsnaa Diagnostics Ltd. Share Price

Pursuant to the Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, Krsnaa Diagnostics has informed that it enclosed a copy of the presentation for the Investors/Analysts on Unaudited Financial Results (Standalone and Consolidated) of the Company for the quarter ended June 30, 2026.

The above information is a part of company’s filings submitted to BSE.  

Pursuant to the provisions of Regulation 29(1) & (2) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, Krsnaa Diagnostics has informed that a meeting of the Board of Directors of the Company is scheduled to be held on Thursday, August 13, 2026 - to consider and approve the unaudited standalone and consolidated financial results of the Company for the quarter ended June 30, 2026. - to consider and evaluate the proposal for raising of funds by way of issuance of one or more instrument(s) / securities which may include equity shares, fully convertible warrants and/or any other eligible securities (convertible / non-convertible) and / or any combinations of securities thereof through permissible modes, including but not limited to a preferential issue on a private placement basis or through any other permissible mode and / or combination thereof as may be considered appropriate, in accordance with the provisions of the Securities and Exchange Board of India (Issue of Capital and Disclosure Requirements) Regulations, 2018 and the Companies Act, 2013, as amended, to the promoter/promoter group, subject to all such shareholders’, regulatory / statutory and other applicable approvals, if any, as may be required including conducting shareholders meeting. Pursuant to the Company's Code of Conduct for Prevention of Insider Trading, the Trading Window for dealing in the securities of the Company shall continue to remain closed until August 15, 2026. This intimation is also being uploaded on the Company’s website at https://krsnaadiagnostics.com/investors/.

The above information is a part of company’s filings submitted to BSE. 

Sai Life Sciences has informed that, pursuant to Regulation 30 read with Schedule III of SEBI Listing Regulations the Board of Directors by the way of Circular Resolution on 01st September 2026, had approved the allotment of 14,600 and 66,000 fully paid-up equity shares having a face value of ₹1 each upon exercise of options granted under ESOP 2008 and MESOP 2018 respectively. Consequent to aforesaid allotment the issued, subscribed, and paid-up equity share capital of the Company has increased from ₹21,23,13,617 to ₹21,23,94,216. The details required under Regulation 10(c) of SEBI (Share Based Employee Benefits and Sweat Equity) Regulations, 2021 (‘SEBI ESOP Regulations 2021’) are enclosed as Annexure-A.

The above information is a part of company’s filings submitted to BSE.